Literature DB >> 29455312

Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphoma.

Nicolas Aide1,2,3, Charline Lasnon4,5, Gandhi Damaj6,7,8.   

Abstract

Mesh：

Year:  2018        PMID： 29455312     DOI： 10.1007/s00259-018-3966-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  Report of the 6th International Workshop on PET in lymphoma.

Authors:  Cristina Nanni; Anne Ségolène Cottereau; Egesta Lopci; Caroline Bodet-Milin; Monica Coronado; Barbara Pro; Wong Seog Kim; Judith Trotman; Sally Barrington; Ulrich Duhrsen; Thierry Vander Borght; Elena Zamagni; Françoise Kraeber-Bodéré; Christina Messiou; Alain Rahmouni; Irène Buvat; Marc Andre; Mark Hertzberg; Wim Oyen; Olivier Casasnovas; Stefano Luminari; Laurent Garderet; Françoise Montravers; Carsten Kobe; Regine Kluge; Annibale Versari; Emanuele Zucca; Philippe Moreau; Bruce Cheson; Corinne Haioun; Andrea Gallamini; Michel Meignan
Journal:  Leuk Lymphoma       Date:  2017-03-07

3.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

Authors:  David W Scott; George W Wright; P Mickey Williams; Chih-Jian Lih; William Walsh; Elaine S Jaffe; Andreas Rosenwald; Elias Campo; Wing C Chan; Joseph M Connors; Erlend B Smeland; Anja Mottok; Rita M Braziel; German Ott; Jan Delabie; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Timothy C Greiner; Betty J Glinsmann-Gibson; Kai Fu; Louis M Staudt; Randy D Gascoyne; Lisa M Rimsza
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

4.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Authors:  Marita Ziepert; Dirk Hasenclever; Evelyn Kuhnt; Bertram Glass; Norbert Schmitz; Michael Pfreundschuh; Markus Loeffler
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

5.  18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.

Authors:  Charline Lasnon; Mohamed Majdoub; Brice Lavigne; Pascal Do; Jeannick Madelaine; Dimitris Visvikis; Mathieu Hatt; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-21       Impact factor: 9.236

6.  Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study.

Authors:  Sylvain Mareschal; Philippe Ruminy; Cristina Bagacean; Vinciane Marchand; Marie Cornic; Jean-Philippe Jais; Martin Figeac; Jean-Michel Picquenot; Thierry Jo Molina; Thierry Fest; Gilles Salles; Corinne Haioun; Karen Leroy; Hervé Tilly; Fabrice Jardin
Journal:  J Mol Diagn       Date:  2015-04-09       Impact factor: 5.568

7.  A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Authors:  William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

Review 8.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236

9.  Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs).

Authors:  Charline Lasnon; Blandine Enilorac; Hosni Popotte; Nicolas Aide
Journal:  EJNMMI Res       Date:  2017-03-31       Impact factor: 3.138

10.  Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.

Authors:  Nicolas Aide; Marjolaine Talbot; Christophe Fruchart; Gandhi Damaj; Charline Lasnon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-07       Impact factor: 9.236
View more
  2 in total

1.  Could we avoid computing TMTV of DLBCL patients in routine practice?

Authors:  Eric Laffon; Roger Marthan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-28       Impact factor: 9.236

2.  18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma.

Authors:  Jakoba J Eertink; Tim van de Brug; Sanne E Wiegers; Gerben J C Zwezerijnen; Elisabeth A G Pfaehler; Pieternella J Lugtenburg; Bronno van der Holt; Henrica C W de Vet; Otto S Hoekstra; Ronald Boellaard; Josée M Zijlstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-18       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.